DK3142666T3 - 5-HT4-receptoragonist til gastroparese - Google Patents

5-HT4-receptoragonist til gastroparese Download PDF

Info

Publication number
DK3142666T3
DK3142666T3 DK15793503.2T DK15793503T DK3142666T3 DK 3142666 T3 DK3142666 T3 DK 3142666T3 DK 15793503 T DK15793503 T DK 15793503T DK 3142666 T3 DK3142666 T3 DK 3142666T3
Authority
DK
Denmark
Prior art keywords
gastroparesis
receptor agonist
agonist
receptor
Prior art date
Application number
DK15793503.2T
Other languages
English (en)
Inventor
Nobuyuki Takahashi
Toshinori Yamamoto
Kaoru Shimada
Hirohide Noguchi
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Application granted granted Critical
Publication of DK3142666T3 publication Critical patent/DK3142666T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15793503.2T 2014-05-16 2015-05-18 5-HT4-receptoragonist til gastroparese DK3142666T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461994432P 2014-05-16 2014-05-16
PCT/JP2015/002478 WO2015174098A1 (en) 2014-05-16 2015-05-18 5-ht4 receptor agonist for gastroparesis

Publications (1)

Publication Number Publication Date
DK3142666T3 true DK3142666T3 (da) 2020-08-31

Family

ID=54479646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15793503.2T DK3142666T3 (da) 2014-05-16 2015-05-18 5-HT4-receptoragonist til gastroparese

Country Status (13)

Country Link
US (1) US9833447B2 (da)
EP (1) EP3142666B1 (da)
JP (2) JP6754033B2 (da)
KR (1) KR102526521B1 (da)
CN (2) CN114344300A (da)
BR (1) BR112016024830A2 (da)
CA (1) CA2948890C (da)
DK (1) DK3142666T3 (da)
ES (1) ES2812100T3 (da)
MX (1) MX373078B (da)
RU (1) RU2708686C2 (da)
TW (2) TW202026002A (da)
WO (1) WO2015174098A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110398541B (zh) * 2018-04-24 2023-03-10 东莞市东阳光动物保健药品有限公司 一种分离和测定枸橼酸马罗匹坦及其光学异构体的方法
CN116940361A (zh) * 2020-12-29 2023-10-24 纽洛佳斯特拉斯公司 美托哌丙嗪及其盐的代谢方法
CN116983314B (zh) * 2023-09-28 2024-02-09 首都医科大学附属北京中医医院 D1-like受体激动剂在制备增强胃动力药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770262B2 (en) * 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
CA2551686C (en) * 2004-01-07 2014-09-23 Ian Irwin Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8816090B2 (en) * 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
MX2009005977A (es) * 2006-12-05 2009-06-17 Pfizer Polimorfos de motilida.
EP2688648B1 (en) * 2011-03-23 2016-01-06 RaQualia Pharma Inc. A 5-ht4 receptor agonist as a prokinetic agent

Also Published As

Publication number Publication date
CN114344300A (zh) 2022-04-15
JP2020109105A (ja) 2020-07-16
EP3142666B1 (en) 2020-06-03
TWI710372B (zh) 2020-11-21
KR20170004978A (ko) 2017-01-11
TW202026002A (zh) 2020-07-16
BR112016024830A2 (pt) 2017-08-15
ES2812100T3 (es) 2021-03-16
MX2016014949A (es) 2017-03-31
TW201625248A (zh) 2016-07-16
JP6754033B2 (ja) 2020-09-09
EP3142666A4 (en) 2018-01-10
US9833447B2 (en) 2017-12-05
CN106456620A (zh) 2017-02-22
EP3142666A1 (en) 2017-03-22
RU2016149357A (ru) 2018-06-20
CA2948890C (en) 2022-05-10
MX373078B (es) 2020-07-03
HK1231414A1 (en) 2017-12-22
CA2948890A1 (en) 2015-11-19
KR102526521B1 (ko) 2023-04-27
JP2017515813A (ja) 2017-06-15
RU2708686C2 (ru) 2019-12-11
WO2015174098A1 (en) 2015-11-19
RU2016149357A3 (da) 2019-01-14
US20170056387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
IL251524B (en) T cell receptors
DK3368060T3 (da) Glugacon-receptor-agonister
IL252258A0 (en) Anti-mutated kras t cell receptors
CL2016002196A1 (es) Receptor antigénico quimérico
DK3072835T3 (da) Fremgangsmåde til fremføring
HRP20181499T1 (hr) Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora
DK3140653T3 (da) Direkte immunhistokemianalyse
FI3198035T3 (fi) Menetelmiä lääkevasteen ennustamiseksi
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
IL276400A (en) Dopamine D3 receptor antagonist compounds
FR3028873B1 (fr) Installation de fractionnement
DK3125898T3 (da) Farmakofor til trail-induktion
DK3386500T3 (da) Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
EP3286210C0 (en) T CELL RECEPTOR
LT3233813T (lt) Į oksatiaziną panašių junginių gavimo būdai
DK3180329T3 (da) Triazoler som nr2b receptorinhibitorer
IL253848A0 (en) Amine compounds as 5-hydroxytryptamine 4 receptor agonists
DK3339706T3 (da) Koblingsanordning til skruekobling
DK3259232T3 (da) Fremgangsmåde til aerogeler
EP3394078A4 (en) INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
DK3183242T3 (da) Substituerede bicykliske forbindelser
EP3394079A4 (en) INHIBITORS OF GLUCOCORTICOIDREZEPTORS
DK3152383T3 (da) Barriere
BR112016027096A2 (pt) compostos de receptores-alvo de serotonina e métodos
DK3310756T3 (da) Thromboxanreceptorantagonister